Ronald Pankau Net Worth

The estimated Net Worth of Ronald A. Pankau is at least $1.86 Million dollars as of 7 November 2019. Mr. Pankau owns over 300 units of CME Inc stock worth over $853,813 and over the last 13 years he sold CME stock worth over $784,387. In addition, he makes $224,182 as Independent Director at CME Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Pankau CME stock SEC Form 4 insiders trading

Ronald has made over 21 trades of the CME Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 300 units of CME stock worth $59,706 on 7 November 2019.

The largest trade he's ever made was selling 500 units of CME Inc stock on 24 February 2017 worth over $61,055. On average, Ronald trades about 201 units every 73 days since 2011. As of 7 November 2019 he still owns at least 3,906 units of CME Inc stock.

You can see the complete history of Mr. Pankau stock trades at the bottom of the page.

Ronald Pankau biography

Ronald A. Pankau serves as Independent Director of the Company. Mr. Pankau has been an independent trader since 1981. He serves as the treasurer and secretary of our political action committee. He also is a member of our finance, executive and risk committees. He has participated in numerous risk management educational programs and as a long-time market participant has significant market risk management experience. Mr. Pankau also serves on our business conduct and pit supervision committees. He is the owner and CEO of JH Best and Sons, a steel fabricating plant.

What is the salary of Ronald Pankau?

As the Independent Director of CME Inc, the total compensation of Ronald Pankau at CME Inc is $224,182. There are 22 executives at CME Inc getting paid more, with Terrence Duffy having the highest compensation of $11,867,200.

How old is Ronald Pankau?

Ronald Pankau is 63, he's been the Independent Director of CME Inc since 2011. There are 11 older and 28 younger executives at CME Inc. The oldest executive at CME Group Inc is Dennis Suskind, 77, who is the Independent Director.

Insiders trading at CME Inc

Over the last 21 years, insiders at CME Inc have traded over $264,111,034 worth of CME Inc stock and bought 77,667 units worth $15,169,350 . The most active insiders traders include Terrence A Duffy, Phupinder Gill, and Bryan T Durkin. On average, CME Inc executives and independent directors trade stock every 10 days with the average trade being worth of $863,868. The most recent stock trade was executed by Bryan T Durkin on 30 August 2024, trading 7,593 units of CME stock currently worth $1,629,382.

What does CME Inc do?

as the world's leading and most diverse derivatives marketplace, cme group (www.cmegroup.com) is where the world comes to manage risk. cme group exchanges offer the widest range of global benchmark products across all major asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. cme group brings buyers and sellers together through its cme globex® electronic trading platform and its trading facilities in new york and chicago. cme group also operates cme clearing, one of the world’s leading central counterparty clearing provider in the world, which offers clearing and settlement services for exchange-traded contracts, as well as for over-the-counter derivatives transactions through cme clearport®. these products and services ensure that businesses everywhere can substantially mitigate counterparty credit risk in both listed and over-the-counter derivatives markets.

Complete history of Mr. Pankau stock trades at CME Inc

CME Inc executives and stock owners

CME Inc executives and other stock owners filed with the SEC include:

• Terrence Duffy,
  Executive Chairman of the Board, Chief Executive Officer
• Michael Spencer,
  Director
• Terrence A. Duffy,
  Chairman & CEO
• John Pietrowhicz,
  Chief Financial Officer
• Sean Tully,
  Senior Managing Director - Financial and OTC Products
• Julie Holzrichter,
  Chief Operating Officer, Senior Managing Director
• Kevin Kometer,
  Chief Information Officer, Senior Managing Director
• John William Pietrowicz M.B.A., CPA,
  Chief Financial Officer
• Kevin D. Kometer,
  Sr. MD & Chief Information Officer
• Julie Holzrichter,
  Sr. MD & COO
• Sunil Cutinho,
  Pres of CME Clearing
• Dennis Suskind,
  Independent Director
• Daniel Glickman,
  Lead Independent Director
• Larry Gerdes,
  Independent Director
• Dennis Chookaszian,
  Independent Director
• Timothy Bitsberger,
  Independent Director
• Howard Siegel,
  Independent Director
• Martin Gepsman,
  Independent Director
• William Shepard,
  Independent Director
• Elizabeth Cook,
  Independent Director
• Terry Savage,
  Independent Director
• Charles Carey,
  Vice Chairman of the Board
• Ronald Pankau,
  Independent Director
• Deborah Lucas,
  Independent Director
• William Hobert,
  Independent Director
• Ana Dutra,
  Independent Director
• Gedon Hertshten,
  Independent Director
• Daniel Kaye,
  Independent Director
• Phyllis Lockett,
  Independent Director
• Yra Harris,
  Independent Director
• Patrick Maloney,
  Independent Director
• Julie Winkler,
  Senior Managing Director, Chief Commercial Officer
• Kendal Vroman,
  Senior Managing Director - International and Optimization Services
• Derek Sammann,
  Senior Managing Director - Commodity and Options
• Kathleen Cronin,
  Senior Managing Director, General Counsel, Corporate Secretary
• Jack Tobin,
  Chief Accounting Officer
• Hilda Piell,
  Chief Human Resource Officer, Senior Managing Director
• Sunil Cutinho,
  President - CME Clearing
• Hilda Harris Piell,
  Sr. MD & Chief HR Officer
• Anita Liskey,
  Sr. Managing Director of Corp. Marketing & Communications
• Kathleen M. Cronin,
  Sr. MD, Gen. Counsel & Corp. Sec.
• John C. Peschier,
  Managing Director of Investor Relations
• Jack Tobin,
  MD & Chief Accounting Officer
• Kimberly S Taylor,
  MD & Pres., Clearing House
• John W. Pietrowicz,
  Sr MD Chief Financial Officer
• Robert Zagotta,
  Director
• Phupinder Gill,
  Managing Director, Clearing
• Jeffrey M. Bernacchi,
  Director
• Leo Melamed,
  Director
• John F Sandner,
  Director
• Alex J Pollock,
  Director
• David J Wescott,
  Director
• James E. Parisi,
  MD & CFO
• Steven E Wollack,
  Director
• William P Ii Miller,
  Director
• James E Oliff,
  Director
• Jill A Harley,
  MD & CAO
• J. Dennis Hastert,
  Director
• Bruce F Johnson,
  Director
• James A Donaldson,
  Director
• C C Ii Odom,
  Director
• Linda Dallas Rich,
  Sr MD Govt Rel Legisl Affairs
• Laurent Paulhac,
  MD OTC Products
• James V. Pieper,
  MD & CAO
• Christopher Stewart,
  Director
• Jackie M Clegg,
  Director
• Scot E. Warren,
  MD Equity Index Prod & Svcs
• Gary M Katler,
  Director
• Mark E Cermak,
  Director
• Joseph Niciforo,
  Director
• Mazen Chadid,
  MD Operations
• James R Krause,
  Man. Director, Operations
• Eileen Keeve,
  Managing Director
• Myron S Scholes,
  Director
• Richard H Redding,
  MD, Products & Services
• Barry C Goldblatt,
  MD Comm Energy & Metal Prods
• Patrick B Lynch,
  Director
• Nancy W Goble,
  Man. Dir & Chief Acc. Off
• Elizabeth Harrington,
  Director
• John Roth Iii Roberts,
  MD & CMO
• Scott Gordon,
  Director
• Robert J Jr Tierney,
  Director
• Robert H Steele,
  Director
• Satish Nandapurkar,
  Managing Director
• Scott L Johnston,
  Man. Dir. & Chief Inf. Off.
• Craig S Donohue,
  EVP & CAO, Office of the CEO
• William G Jr Salatich,
  Director
• Robert F Corvino,
  Director
• John P Iii Davidson,
  MD & Chief Corp Dev Officer
• David G Gomach,
  Managing Director & CFO
• John L Pietrzak,
  Director
• James J Mcnulty,
  President & CEO
• James E Newsome,
  Director
• Scott Robinson,
  MD, Corporate Development
• Bryan T Durkin,
  Director
• Michael G. Dennis,
  Director
• Patrick J Mulchrone,
  Director
• Rahael Seifu,
  Director
• Suzanne Sprague,
  Sr MD Global Head of Clearing
• Timothy Francis Mc Court,
  Sr MD Global Head Equity & FX
• Ken Vroman,
  Chief Transformation Officer
• Jonathan L Marcus,
  Sr MD General Counsel
• Kathryn Benesh,
  Director
• Harold Eugene Jr. Ford,
  Director
• Lynne Fitzpatrick,
  Sr MD Chief Financial Officer